GSK reaffirmed its 2026 guidance following a strong first quarter, expecting core operating profit and earnings per share to grow 7-9% at constant exchange rates. The company projects turnover growth of 3-5%, driven mainly by a 14% rise in Specialty Medicines sales, especially Oncology and HIV treatments. Vaccines sales increased 4%, led by the shingles vaccine Shingrix, while General Medicines saw a 6% decline. GSK also highlighted progress in its drug pipeline with regulatory filings and fast-track designations, and declared a quarterly dividend of 17p per share, aiming for 70p for the full year.
UBS maintains a neutral rating on GSK ahead of its Q2 results, focusing on CEO Luke Miels' upcoming strategy update. UBS expects little market reaction to the earnings, highlighting concerns over a £4 billion gap between GSK's sales target and foreca...
UBS maintains a neutral rating on GSK ahead of its Q2 results and a strategy update from new CEO Luke Miels, focusing on whether he can deliver GSK's target of over £40 billion in risk-adjusted sales by 2031. UBS forecasts slightly below consensus fo...
